Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New treatment regimen for multidrug-resistant tuberculosis
PACTR201409000848428Not yet recruiting
- Sponsor
- University of Cape Town Lung Institute
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of linezolid, bedaquiline and levofloxacin in Tuberculosis (TB) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Cape Town Lung Institute. Primary endpoint: Proportion of patients with favourable outcome. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
linezolidbedaquilinelevofloxacin
03
Conditions
Tuberculosis (TB)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201409000848428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201409000848428.